TransCode Therapeutics Inc(RNAZ) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -50.69 | Insider Own | 5.56% | Shs Outstand | 16.9M | Perf Week | -4.72% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 16.0M | Perf Month | 2.08% |
| Enterprise Value | 0.19B | PEG | - | EPS next Q | - | Inst Own | 0.2% | Short Float | 0.33% | Perf Quarter | -71.08% |
| Income | -0.05B | P/S | - | EPS this Y | - | Inst Trans | 0.45% | Short Ratio | 0.97 | Perf Half Y | -80.22% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -53.79% | Short Interest | 0.05M | Perf YTD | -74.89% |
| Book/sh | -27.38 | P/C | 3.47 | EPS past 3/5Y | 96.25% 79.17% | ROE | -59.28% | 52W High | -87.71% ($13.96) | Perf Year | -86.2% |
| Cash/sh | 0.49 | P/FCF | - | Sales past 3/5Y | - | ROIC | -30.96% | 52W Low | 12.83% ($1.52) | Perf 3Y | -99.99% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 86.74% | Gross Margin | - | Volatility(W/M) | 10.16% 10.09% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.2 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.97 | EPS Q/Q | -39.81% | Profit Margin | - | RSI (14) | 43.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.97 | Sales Q/Q | - | SMA20 | 0.91% ($1.7) | Beta | 1.27 | Target Price | $280 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -14.95% ($2.02) | Rel Volume | 0.52 | Prev Close | $1.66 |
| Employees | 12 | LT Debt/Eq | 0 | EPS/Sales Surpr. | 67.35% -100% | SMA200 | -72.91% ($6.35) | Avg Volume(3M) | 0.05M | Price | $1.72 |
| IPO | 2021/7/9 | Option/Short | No/Yes | Trades | 199 | Volume | 27,972 | Change | 3.31% |
🧬 TransCode Therapeutics () is a U.S. clinical-stage biotech developing RNA therapeutics that target microRNA-10b (miR-10b), which plays a key role in cancer metastasis and tumor evolution. Its lead candidate, TTX-MC138, met safety and pharmacokinetic endpoints in Phase 1a for metastatic solid tumors. It is a small-cap RNA therapeutics name that is initiating a Phase 2a dose-expansion trial within the Quantum Leap PRE-I-SPY platform, for which the company is pursuing the acquisition of Calogics.
Over the past 1 year, on the lower side
88% below its 1-year high.
Traded less than usual. That is 52% of its average volume.
RNAZ has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VXF Vanguard Extended Market Index ETF <0.01% It ranks #454 of 594 in the industry
Based on market cap of $29M.
ALGS#452 Aligos Therapeutics Inc $30M PER - 
BCTX#453 BriaCell Therapeutics Corp $30M PER - RNAZ#454 TransCode Therapeutics Inc $29M PER - 
CVM#455 Cel-Sci Corp $28M PER - 
ABVC#456 ABVC BioPharma Inc $28M PER - 
FAQ
What kind of company is RNAZ?
RNAZ belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RNAZ?
The market cap of RNAZ is approximately $29M, ranking 5,105 within its sector.
What is the 52-week high and low for RNAZ?
RNAZ has recorded a 52-week high of $13.96 and a low of $1.52.
